Small UK study suggests that depression does not have an impact on hepatitis C treatment outcomes in people co-infected with HIV

Michael Carter
Published: 04 January 2013

Depression does not influence hepatitis C treatment outcomes in people co-infected with HIV, according to the results of a small study conducted in Brighton and presented to the recent European Association for the Study of the Liver (EASL) conference, HIV and the Liver.

However, the investigators from the Royal Sussex County Hospital caution their results are only preliminary and need to be tested in a larger patient cohort.

Pegylated interferon and ribavirin are the backbone of current treatment regimes for hepatitis C infection. This therapy is associated with a high rate of depression, which often lead to the discontinuation of treatment. It is therefore recommended that patients should be screened for symptoms of depression before initiating therapy for hepatitis C, and prophylactic antidepressant treatment should be considered for people with existing depression. Antidepressant treatment and psychological support should also be offered to people who develop depression when taking anti-hepatitis C drugs.

The impact of depression and antidepressant therapy on treatment outcomes in people co-infected with HIV and hepatitis C is unclear. Doctors in Brighton therefore designed a prospective study involving 38 people who were about to start treatment with pegylated interferon and ribavirin. Their aim was to see if depression at baseline or during treatment influenced outcomes.

All the participants received hepatitis C therapy lasting 24 weeks. An end-of-treatment response was an undetectable hepatitis C viral load at week 24. A sustained virological response – or cure – was an undetectable hepatitis C 24 weeks after the completion of treatment.

Most of the participants (n = 36; 95%) were men and their mean age was 41 years. Injecting drug use was the main mode of hepatitis C transmission (n = 35; 92%). Almost two-thirds (n = 23; 61%) were infected with the harder-to-treat hepatitis C genotypes (1 and 4).

Before starting hepatitis C therapy, all the participants were assessed for depression using the Structured Clinical Interview for DSMIV and the Hamilton Depression Rating Scale. Three participants (8%) were diagnosed with major depression using these assessment tools.

Some 32 participants were diagnosed with depression after starting hepatitis C treatment and 17 (46%) received therapy with antidepressants.  

The participants did well on hepatitis C therapy. An end-of-treatment response was achieved by 36 individuals (95%) and a sustained virological response by 32 people (87%).

All three participants with depression at baseline had both an end-of-treatment and a sustained virological response.

The emergence of depression during treatment did not influence treatment outcomes. Antidepressant therapy had no impact on outcomes in the patients who did become depressed.

“No significant influence was found for depressive disorder at baseline or emerging during treatment on viral response,” comment the investigators. “Antidepressant exposure did not appear to influence viral response.”

They call for further research to validate their findings. Nevertheless, the investigators believe their results support the “management of depressive disorder during interferon alpha plus ribavirin treatment. This will reduce depression associated interferon treatment dropout.”


Fialho R et al. The effect if depressive disorder on viral clearance in coinfected HIV/HCV patients undergoing interferon alpha treatment. EASL Monothematic Conference: HIV and the Liver, 2012.

Hepatitis information

For more information on hepatitis visit

Infohep is a project we're working on with the World Hepatitis Alliance and the European Liver Patients Association.

Visit >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.